Tepezza Mass Tort Case Leads
Connect with patients who suffered permanent hearing loss or tinnitus after Tepezza infusions for thyroid eye disease.
Tepezza Hearing Loss & Tinnitus Litigation
Tepezza (teprotumumab) is an infusion drug approved by the FDA in January 2020 to treat thyroid eye disease (TED). Lawsuits allege the manufacturer, Horizon Therapeutics (now part of Amgen), failed to adequately warn patients and physicians that the drug can cause permanent hearing loss, tinnitus, and other hearing-related injuries. The cases are consolidated in federal multidistrict litigation MDL 3079, before Judge Thomas M. Durkin in the Northern District of Illinois. As of 2026 the litigation remains active, with bellwether proceedings underway and new claimants still being accepted.
Associated Conditions
- Permanent or partial hearing loss
- Tinnitus (persistent ringing in the ears)
- Eustachian tube dysfunction
- Autophony (hearing your own voice abnormally loud)
- Plugged or blocked ear sensation
- Muffled hearing or hyperacusis
- Sensorineural hearing impairment
Claimant Eligibility
- Received one or more Tepezza (teprotumumab) infusions for thyroid eye disease
- Diagnosed with hearing loss, tinnitus, or another hearing-related injury after treatment
- Symptoms appeared during or after the Tepezza infusion course
- Hearing damage can be documented through medical or audiology records
- Claim filed within the applicable statute of limitations for your state
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Tepezza legal marketing campaigns: how we acquire cases
Tepezza case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Running a Tepezza mass tort marketing campaign
Common questions from law firms about Tepezza lawsuit lead generation and campaign management.
- What does a Tepezza mass tort marketing campaign include?
- A Tepezza mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Tepezza case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Tepezza mass tort case leads?
- Tepezza mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Tepezza legal marketing campaigns cost?
- Tepezza legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Tepezza leads exclusive to my firm?
- Yes. Every Tepezza lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Tepezza claimants qualified before delivery?
- Each Tepezza claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Tepezza case acquisition program scale?
- A Tepezza mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
Get Tepezza campaign pricing on a 30-minute call
We will walk your Tepezza case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.